[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@pick1998_2 Nick zheng

Nick zheng posts on X about $srpt, $vstm, discount, $clrb the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXXX +256%
• X Month XXXXXX +182%
• X Months XXXXXX +385%
• X Year XXXXXX -XX%

Mentions: X #

• X Week X +60%
• X Month XX +12%
• X Months XX +575%
• X Year XX -XXXX%

Followers: XXXXX #

• X Week XXXXX +0.33%
• X Month XXXXX +1.30%
• X Months XXXXX +4.20%
• X Year XXXXX +5.70%

CreatorRank: XXXXXXXXX #

Social Influence #

---

Social category influence stocks XXXX% finance XXXX%

Social topic influence $srpt 8.33%, $vstm 8.33%, discount 8.33%, $clrb 4.17%, $mreo 4.17%, drugs 4.17%, stocks 4.17%, $urgn 4.17%, c3 4.17%, $apls XXXX%

Top accounts mentioned or mentioned by @fireworkstrades @nolastevedore @achillestxcom @buffalo51766917 @stocksdd @ravi1982nl

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Apellis Pharmaceuticals, Inc. Common Stock (APLS)

Top Social Posts #

---

Top posts by engagements in the last XX hours

"$SRPT pivoting from AAV gene therapy/RNA splicing to siRNA therapies and broadened applications. A good direction. strong buy under 30"
@pick1998_2 on X 2025-07-16 21:45:52 UTC 6910 followers, 7084 engagements

"$CLRB insiders are buying after r-split and financing at discount. Will FDA BTD bring this biotech stock back to life"
@pick1998_2 on X 2025-07-03 16:55:43 UTC 6903 followers, 1340 engagements

"$MREO buy it now at XX% discount and forget it for a few months. Very likely it will recover when topline final data are announced by end of this year"
@pick1998_2 on X 2025-07-14 15:01:15 UTC 6910 followers, 3786 engagements

"$VSTM $URGN keep adding these two cheap biotech stocks with unique approved drugs for specific cancers"
@pick1998_2 on X 2025-07-03 16:53:26 UTC 6910 followers, 1694 engagements

"$APLS PUDFA 7/28/25 sNDA of EMPAVELI(pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) which are severe and rare kidney diseases. Priority Review. Approval should come. It should help reach profitability"
@pick1998_2 on X 2025-07-18 15:32:36 UTC 6910 followers, XXX engagements

"$CAPR $SRPT Now new FDA admin want definitive efficacy of Decamiocel for DMD. Will this idea/thought help $SRPT's Elevidys to stay on market which targets the root of the disease"
@pick1998_2 on X 2025-07-11 16:31:50 UTC 6902 followers, 2647 engagements